The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04965675
Recruitment Status : Recruiting
First Posted : July 16, 2021
Last Update Posted : April 11, 2024
Sponsor:
Information provided by (Responsible Party):
H. Lundbeck A/S

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

Condition or disease Intervention/treatment Phase
Chronic Migraine in Children Drug: Eptinezumab Drug: Placebo Phase 3

Detailed Description:
The study includes a single intravenous (IV) infusion of the study drug and consists of a screening period (4 weeks), a double-blind, placebo-controlled period (12 weeks), and a safety follow-up period (8 weeks). Participants confirmed eligible will be randomized (1:1:1) to receive a single IV infusion of either eptinezumab 300 milligrams (mg) dose (weight adjusted; targeting adult exposure after 300 mg IV), eptinezumab 100 mg (weight adjusted; targeting adult exposure after 100 mg IV), or placebo at randomization visit. The doses will be adjusted for the participant's body weight.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 285 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine
Actual Study Start Date : June 30, 2021
Estimated Primary Completion Date : October 31, 2024
Estimated Study Completion Date : October 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Migraine
MedlinePlus related topics: Migraine

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Eptinezumab 300 mg
Participants will receive a single IV infusion of eptinezumab 300 mg (weight adjusted).
 Drug: Eptinezumab
Eptinezumab will be administered per dose and schedule specified in the arm.
Other Name: Vyepti
Experimental: Eptinezumab 100 mg
Participants will receive a single IV infusion of eptinezumab 100 mg (weight adjusted).
 Drug: Eptinezumab
Eptinezumab will be administered per dose and schedule specified in the arm.
Other Name: Vyepti
Placebo Comparator: Placebo
Participants will receive a single IV infusion of placebo matching to eptinezumab.
 Drug: Placebo
Placebo matching to eptinezumab will be administered per schedule specified in the arm.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12 [ Time Frame: Baseline, Weeks 1-12 ]

Secondary Outcome Measures :
  1. Percentage of Participants With 50% Reduction From Baseline in MMDs Averaged Over Weeks 1-12 [ Time Frame: Baseline up to Weeks 1-12 ]
  2. Percentage of Participants With Migraine on the Day After Dosing (Day 1) [ Time Frame: Day 1 ]
  3. Change From Baseline in MMDs With Use of Acute Medication Averaged Over Weeks 1-12 [ Time Frame: Baseline, Weeks 1-12 ]
  4. Percentage of Participants With 75% Reduction From Baseline in MMDs Averaged Over Weeks 1-12 [ Time Frame: Baseline up to Weeks 1-12 ]
  5. Percentage of Participants With 75% Reduction From Baseline in MMDs Averaged Over Weeks 1-4 [ Time Frame: Baseline up to Weeks 1-4 ]
  6. Percentage of Participants With 50% Reduction From Baseline in MMDs Averaged Over Weeks 1-4 [ Time Frame: Baseline up to Weeks 1-4 ]
  7. Change From Baseline in Monthly Headache Days Averaged Over Weeks 1-12 [ Time Frame: Baseline, Weeks 1-12 ]
  8. Change From Baseline in Rate of Migraines With Severe Pain Intensity Averaged Over Weeks 1-12 [ Time Frame: Baseline, Weeks 1-12 ]
  9. Change From Baseline in Days With Use of Acute Medication Averaged Over Weeks 1-12 [ Time Frame: Baseline, Weeks 1-12 ]
  10. Change From Baseline in Pediatric Migraine Disability Assessment Questionnaire (PedMIDAS) Score Averaged Over Weeks 1-12 [ Time Frame: Baseline, Weeks 1-12 ]
  11. Free Eptinezumab Plasma Concentration [ Time Frame: Randomization ( pre-dose [Week 0]), Week 8, Week 12, and safety follow up visit (Week 20) ]
  12. Number of Participants With Specific Anti-Eptinezumab Antibodies (Anti-Drug Antibodies [ADA]) [ Time Frame: From randomization (Week 0) up to Week 20 ]
  13. Number of Participants With Specific Anti-Eptinezumab Antibodies for Neutralizing Activity (NAb) [ Time Frame: From randomization (Week 0) up to Week 20 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The participant has a diagnosis of migraine (with or without aura) as defined by International Classification of Headache Disorders 3 (ICHD-3) guidelines with history of chronic migraine, of at least 6 months prior to the screening visit.
  • During the 28-day screening period, the participant must adequately complete the headache eDiary on at least 23 of the 28 days following the screening visit.
  • During the 28-day screening period, the participant must have ≥15 to ≤26 headache days, of which at least 8 are migraine days as documented in the eDiary.

Exclusion Criteria:

  • The participant has previously been randomised in this study and exposed to eptinezumab.
  • The participant has been exposed to any monoclonal antibody treatment (including exposure in a study) <6 months prior to the screening visit.
  • The participant has been exposed to another calcitonin gene-related peptide (CGRP) antibody (including exposure in a study investigating a CGRP antibody) <6 months prior to the screening visit.
  • The participant has a history or diagnosis of complicated migraine (ICHD-3 version, 2018), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, ophthalmoplegic migraine, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration; for example >60 minutes).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04965675


Contacts
Layout table for location contacts
Contact: Email contact via H. Lundbeck A/S +45 36301311 LundbeckClinicalTrials@Lundbeck.com

Locations
Show Show 65 study locations
Sponsors and Collaborators
H. Lundbeck A/S
Investigators
Layout table for investigator information
Study Director: Email contact via H. Lundbeck A/S H. Lundbeck A/S
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: H. Lundbeck A/S
ClinicalTrials.gov Identifier: NCT04965675    
Other Study ID Numbers: 19356A
2020-001009-22 ( EudraCT Number )
First Posted: July 16, 2021    Key Record Dates
Last Update Posted: April 11, 2024
Last Verified: April 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
 Brain Diseases
Central Nervous System Diseases
Nervous System Diseases